Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy

European Urology

Volumn 54, Issue 1, 2008, Pages 88-96

  Loeb, Stacy ^a   Roehl, Kimberly A ^b   Viprakasit, Davis P ^c   Catalona, William J ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adjuvant radiation; Progression; Prostate cancer; Radical prostatectomy; Salvage radiation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATECTOMY; SALVAGE THERAPY; SEMINAL VESICLE;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 44149099743     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.03.066     Document Type: Article

References (15)

1. Karakiewicz P.I., Eastham J.A., Graefen M., et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 66 (2005) 1245-1250
2. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 (2002) 528-534
3. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910-914
4. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
5. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
6. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
7. Wiegel T., Bottke D., Willich N., et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT2 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol Suppl 23 (2005) 4513
8. Slawin K.M. Radiation therapy after radical prostatectomy: why patience is a virtue! The case for salvage radiation therapy. Rev Urol 4 (2002) 90-94
9. Van Cangh P.J., Richard F., Lorge F., et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol 159 (1998) 164-166
10. Song D.Y., Thompson T.L., Ramakrishnan V., et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 60 (2002) 281-287
11. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
12. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041
13. Collette L., van Poppel H., Bolla M., et al. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 41 (2005) 2662-2672
14. Van der Kwast T.H., Bolla M., Van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25 (2007) 4178-4186
15. D'Amico A.V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284 (2000) 1280-1283